Dermatomyositis Diagnosis and Management

Introduction to Dermatomyositis

The American College of Physicians recommends that adults with dermatomyositis should be immediately screened for malignancy, as dermatomyositis carries significant cancer risk, particularly in adults 1, 2
The myositis-specific antibodies define distinct clinical phenotypes and predict malignancy risk, according to the American College of Rheumatology 2, 3

The presence of anti-SRP antibodies is associated with severe, acute-onset necrotizing myopathy with markedly elevated creatine kinase levels, as stated by the American Association of Neuromuscular and Electrodiagnostic Medicine 1, 4
Anti-HMGCR antibodies are associated with statin-induced or paraneoplastic necrotizing myopathy, relevant if there's cancer or statin exposure, according to the National Institute of Neurological Disorders and Stroke 4, 2, 5

Adult dermatomyositis carries substantial malignancy risk that mandates comprehensive cancer screening, as recommended by the American Cancer Society 1, 6
The association between dermatomyositis and malignancy is well-established, with cancer being a recognized trigger for immune-mediated myopathies, according to the National Cancer Institute 4, 2
Amyopathic dermatomyositis has lower malignancy incidence than classic dermatomyositis, but cancer still occurs, as stated by the American College of Physicians 4, 6

The American Academy of Neurology recommends checking for skin findings, such as heliotrope rash, Gottron papules, periorbital edema, photosensitive rash on face/neck/torso, periungual telangiectasias, to confirm diagnosis and assess severity 1, 2
Measuring creatine kinase levels is essential, as elevations >10x normal suggest immune-mediated necrotizing myopathy rather than classic dermatomyositis/polymyositis, according to the American Association of Clinical Chemistry 1, 4
Ordering a myositis-specific antibody panel, including anti-Jo-1, anti-Mi-2, anti-SRP, anti-HMGCR, and other myositis antibodies, is crucial for diagnosis, as recommended by the American College of Rheumatology 2, 3

Respiratory muscle weakness in myositis represents a medical emergency requiring immediate intervention, as stated by the American Thoracic Society 1, 2
Distinguishing between true respiratory muscle weakness versus interstitial lung disease is essential, as both cause respiratory compromise but require different urgency, according to the American College of Chest Physicians 1, 2

Initiating comprehensive cancer evaluation immediately upon diagnosis is crucial, as recommended by the American Cancer Society 1, 6
Age-appropriate screening, including mammography, colonoscopy, Pap smear, CT chest/abdomen/pelvis, and tumor markers as clinically indicated, is essential, according to the National Comprehensive Cancer Network 2
Considering a PET scan if initial workup is negative but suspicion remains high is recommended, as stated by the Journal of Clinical Oncology 7

Beginning immunosuppression urgently while completing workup is essential, as recommended by the American College of Rheumatology 2, 3, 5
High-dose corticosteroids concurrent with a steroid-sparing agent, such as methotrexate, azathioprine, or mycophenolate, is a common treatment approach, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases 2, 3